These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 9361957)

  • 21. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of liposomal anthracyclines: from basics to clinical applications.
    Gabizon A; Goren D; Cohen R; Barenholz Y
    J Control Release; 1998 Apr; 53(1-3):275-9. PubMed ID: 9741935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.
    Allen TM; Cheng WW; Hare JI; Laginha KM
    Anticancer Agents Med Chem; 2006 Nov; 6(6):513-23. PubMed ID: 17100556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in nano-delivery systems for doxorubicin: an updated insight.
    Kanwal U; Irfan Bukhari N; Ovais M; Abass N; Hussain K; Raza A
    J Drug Target; 2018 Apr; 26(4):296-310. PubMed ID: 28906159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
    J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil).
    Skubitz KM; Skubitz AP
    Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
    Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
    J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
    Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
    Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
    Soloman R; Gabizon AA
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):21-32. PubMed ID: 18501085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
    Dvorak J; Zoul Z; Melichar B; Petera J; Vesely P; Vosmik M; Dolezel M
    J Chemother; 2004 Nov; 16 Suppl 5():34-6. PubMed ID: 15675474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
    Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
    Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.